Clinical Trial

SAR447971 First-in-human Study

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation. MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants. MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants. Number of participants - The total expected number of healthy participants is approximately 94 and the total number of HS participants is expected to be approximately 20. * SAD20411 will enroll up to 46 participants * MAD20412 will enroll up to 48 participants * MAD24339 will enroll up to 20 participants Duration of study - The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.
Trial Details
NCT Number NCT07629336
Lead Sponsor Sanofi
Collaborators: Kymera Therapeutics, Inc.
Conditions Hidradenitis, Healthy Volunteers
Enrollment 114 participants
Start Date 2026-05-26
Primary Completion 2028-02-16 (estimated)
Study Completion 2028-02-16 (estimated)
Updated on ClinicalTrials.gov 2026-06-05